雷利度胺治疗难治复发急性粒细胞白血病临床观察

Clinical Observation of Lenalidomide Treat Relapsed or Refractory Acute Myeloblastic Leukemia

目的:观察雷利度胺治疗难治复发急性粒细胞白血病的疗效及不良反应。方法:给予雷利度胺单药治疗,雷利度胺50mg/d,口服给药,连续给药21天,28天为一个疗程。结果:应用雷利度胺4(2～6)个疗程,5例有效,2例获得完全缓解,2例部分缓解,1例因疾病迅速进展死亡退出试验。不良反应主要为疲乏4例,中性粒细胞减少性发热3例,中粒细胞减少4例,血小板减少1例,贫血1例。结论:应用雷利度胺治疗难治复发白血病有效,不良反应轻微且易于耐受。

Objective： To observe toxicities and efficacy in patients relapsed or refractory acute myeloblastic leukemia with lenalidomide. Methods： Lenalidomide was given orally at doses of 50mg daily on days 1 through 21 of 28-day cycles. Results： Six Patients were given a median of four prior therapies＇ （range, two to six therapies）, five patients with AML responded. Two of 6 patients achieved complete remission （CR）, two of 6 patients achieved partial remission （PR）, one of 6 patients achieved Peripheral blood improvement,One patient had disease progression death. Toxicities of lenalidomide were Fatigue （4/6）, febrile neutropenia （3/6）, neutropenia （4/6）, thrombocytopenia（1/6）, anemia（I/6）. Conclusions： Lenalidomide has significant activity in relapsed or refractory acute myeloblastic leukemia patients and the toxicities was active with relatively low toxicity in patients with relapsed/refractory AML.